Access the full text.
Sign up today, get DeepDyve free for 14 days.
K. Lindfors, C. Rosenquist (1995)
The cost-effectiveness of mammographic screening strategies.JAMA, 274 11
A. Williams, B. Balasooriya, D. Day (1982)
Polyps and cancer of the large bowel: a necropsy study in Liverpool.Gut, 23
Larry Kessler, Eric Feuer, Martin Brown (1991)
Projections of the breast cancer burden to U.S. women: 1990-2000.Preventive medicine, 20 1
W. Viscusi (1992)
Smoking: Making the Risky Decision
N. Stout, M. Rosenberg, A. Trentham-Dietz, Maureen Smith, Stephen Robinson, D. Fryback (2006)
Retrospective cost-effectiveness analysis of screening mammography.Journal of the National Cancer Institute, 98 11
Ruth Etzioni, A. Tsodikov, A. Mariotto, A. Szabo, S. Falcon, Jake Wegelin, Dante diTommaso, K. Karnofski, R. Gulati, D. Penson, E. Feuer (2008)
Quantifying the role of PSA screening in the US prostate cancer mortality declineCancer Causes & Control, 19
Explaining Secular Trends in Colorectal Cancer Incidence and Mortality with an Empirically-Calibrated Microsimulation Model
E. Elbasha, E. Dasbach, R. Insinga (2007)
Model for Assessing Human Papillomavirus Vaccination StrategiesEmerging Infectious Diseases, 13
J. Strong, A. Reif, P. Correa, W. Johnson (1977)
The epidemiology of colorectal polyps. Prevalence in New Orleans and International comparisonsCancer, 39
U. Force (2004)
Lung Cancer Screening: Recommendation StatementAnnals of Internal Medicine, 140
John Bailar, H. Gornik (1997)
Cancer undefeated.The New England journal of medicine, 336 22
N. Breslow, Chang Cw, G. Dhom, Drury Ra, Franks Lm, B. Gellei, Lee Ys, S. Lundberg, B. Sparke, Sternby Nh, H. Tulinius (1977)
Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, FranceInternational Journal of Cancer, 20
Conclusion 515-636
(2007)
Cancer Trends Progress Report—2007 Update, http://progressreport
G. Colditz, Kathy Atwood, K. Emmons, R. Monson, W. Willett, D. Trichopoulos, D. Hunter (2004)
Harvard Report on Cancer Prevention Volume 4: Harvard Cancer Risk IndexCancer Causes & Control, 11
C. Earle, B. Neville, M. Landrum, J. Ayanian, S. Block, J. Weeks (2004)
Trends in the aggressiveness of cancer care near the end of life.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 2
G. Riley, A. Potosky, J. Lubitz, L. Kessler (1995)
Medicare Payments from Diagnosis to Death for Elderly Cancer Patients by Stage at DiagnosisMedical Care, 33
C. Coley, M. Barry, C. Fleming, M. Fahs, A. Mulley (1997)
CLINICAL GUIDELINES: PART II: Early Detection of Prostate Cancer: Part IIAnnals of Internal Medicine, 126
Cancer Mortality for the Year 2015
Feuer (for the Cancer Intervention and Surveillance Modeling Network Collaborators)
K. Anderson, J. Jacobson, D. Heitjan, J. Zivin, D. Hershman, A. Neugut, V. Grann (2006)
Cost-Effectiveness of Preventive Strategies for Women with a BRCA1 or a BRCA2 MutationAnnals of Internal Medicine, 144
Cutler , Fabian Lange , Ellen Meara , Seth Richards - Shubik
L. Abenhaim (2003)
[Progress against cancer!].Revue d'epidemiologie et de sante publique, 51 1 Pt 1
Russell Harris, K. Lohr (2002)
Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 137
Ries Lag, D. Harkins, Martin Krapcho, A. Mariotto, Miller Ba, E. Feuer, L. Clegg, M. Eisner, Horner Mj, N. Howlader, Matthew Hayat, B. Hankey, Edwards Bk, Seer site (2006)
SEER Cancer Statistics Review, 1975-2003, National Cancer Institute. Bethesda, MD,
R. Rickert, O. Auerbach, L. Garfinkel, E. Hammond, J. Frasca (1979)
Adenomatous lesions of the large bowel: An autopsy surveyCancer, 43
O. Barash, N. Peled, F. Hirsch, H. Haick (2009)
Sniffing the unique "odor print" of non-small-cell lung cancer with gold nanoparticles.Small, 5 22
G. Glaeske (2010)
Pharmakoökonomie in der Hämatologie und OnkologieDer Onkologe, 16
R. Woodward, Martin Brown, Susan Stewart, K. Cronin, D. Cutler (2007)
The value of medical interventions for lung cancer in the elderlyCancer, 110
K. Cronin, S. Plevritis, D. Fryback (2005)
Effect of screening and adjuvant therapy on mortality from breast cancerThe New England Journal of Medicine, 353
G. Gallus, C. Mandelli, M. Marchi, G. Radaelli (1986)
On surveillance methods for congenital malformations.Statistics in medicine, 5 6
M. Pignone, S. Saha, T. Hoerger, J. Mandelblatt (2002)
Cost-Effectiveness Analyses of Colorectal Cancer ScreeningAnnals of Internal Medicine, 137
Kevin Murphy, R. Topel (2005)
The Value of Health and LongevityJournal of Political Economy, 114
P. Mahadevia, L. Fleisher, K. Frick, J. Eng, S. Goodman, N. Powe (2003)
Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis.JAMA, 289 3
(2008)
The NIH Almanac, 2008
L. Ries, D. Harkins, Martin Krapcho, A. Mariotto, B. Miller, E. Feuer, L. Clegg, M. Eisner, Marie-Josèphe Horner, N. Howlader, Matthew Hayat, B. Hankey, B. Edwards (2006)
SEER Cancer Statistics Review, 1975-2003
A. Haus (2002)
Historical Technical Developments in MammographyTechnology in Cancer Research & Treatment, 1
C. Coley, M. Barry, C. Fleming, M. Fahs, A. Mulley (1997)
Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians.Annals of internal medicine, 126 6
C. Anderson (1992)
Zero-sum gameNature, 356
H. Welch, W. Black (1997)
Using Autopsy Series To Estimate the Disease Reservoir for Ductal Carcinoma in Situ of the Breast: How Much More Breast Cancer Can We Find?Annals of Internal Medicine, 127
J. Elmore, M. Barton, Victoria Moceri, Sarah Polk, P. Arena, S. Fletcher (1998)
Ten-year risk of false positive screening mammograms and clinical breast examinations.The New England journal of medicine, 338 16
T. Philipson, Gary Becker, Dana Goldman, Kevin Murphy (2009)
The value of life near its end and terminal care by
J. Higginson (1974)
International agency for research on cancer.Archives of pathology, 98 5
E. Feuer, R. Merrill, B. Hankey (1999)
Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality.Journal of the National Cancer Institute, 91 12
(2006)
Bounds in Competing Risk Models and the War on Cancer
T. Holford, Z. Zhang, T. Zheng, L. McKay (1996)
A model for the effect of cigarette smoking on lung cancer incidence in Connecticut.Statistics in medicine, 15 6
P. Scardino, R. Weaver, M. Hudson (1992)
Early detection of prostate cancer.Human pathology, 23 3
M. Schoenbaum (1997)
Do smokers understand the mortality effects of smoking? Evidence from the Health and Retirement Survey.American journal of public health, 87 5
A. Eschenbach (2005)
Keynote speech: Progress with a purposeCancer, 104
David Laibson (1997)
Golden Eggs and Hyperbolic DiscountingQuarterly Journal of Economics, 112
Ary, B. B, Árton, Ictoria, M. M., Oceri, Hilip, A. J., Renã (2000)
TEN-YEAR RISK OF FALSE POSITIVE SCREENING MAMMOGRAMS AND CLINICAL BREAST EXAMINATIONS
N. Breen, Kathleen Cronin, H. Meissner, S. Taplin, F. Tangka, Jasmin Tiro, T. McNeel (2007)
Reported drop in mammographyCancer, 109
L. Hughes (1968)
The Incidence of Benign and Malignant Neoplasms of the Colon and Rectum: A Post-Mortem Study.The Australian and New Zealand journal of surgery, 38 1
I. Vogelaar, M. Ballegooijen, D. Schrag, R. Boer, S. Winawer, J. Habbema, A. Zauber (2006)
How much can current interventions reduce colorectal cancer mortality in the U.S.?Cancer, 107
J. Bailar, E. Smith (1986)
Progress against cancer?The New England journal of medicine, 314 19
Abstract President Nixon declared what came to be known as the “war on cancer” in 1971 in his State of the Union address. At first the war on cancer went poorly: despite a substantial increase in resources, age-adjusted cancer mortality increased by 8 percent between 1971 and 1990, twice the increase from 1950 through 1971. However, between 1990 and 2004, age-adjusted cancer mortality fell by 13 percent. This drop translates into an increase in life expectancy at birth of half a year—roughly a quarter of the two-year increase in life expectancy over this time period and a third of the increase in life expectancy at age 45. The decline brings cancer mortality to its lowest level in 60 years. In the war on cancer, optimism has replaced pessimism. In this paper, I evaluate the reasons for the reduction in cancer mortality. I highlight three factors as leading to improved survival. Most important is cancer screening: mammography for breast cancer and colonoscopy for colorectal cancer. These technologies have had the largest impact on survival, at relatively moderate cost. Second in importance are personal behaviors , especially the reduction in smoking. Tobacco-related mortality reduction is among the major factors associated with better health, likely at a cost worth paying. Third in importance, and more controversial, are treatment changes . Improvements in surgery, radiation, and chemotherapy have contributed to improved survival for a number of cancers, but at high cost. The major challenge for cancer care in the future is likely to be the balancing act between what we are able to do and what it makes sense to pay for.
Journal of Economic Perspectives – American Economic Association
Published: Nov 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.